A Review of Two Regulatory Approved Anti-CD19 CAR T-Cell Therapies in Diffuse Large B-Cell Lymphoma: Why Are Indirect Treatment Comparisons Not Feasible?

Anti-CD19 chimeric antigen receptor (CAR) T-cell therapies can be effective for diffuse large B-cell lymphoma (DLBCL), a cancer with limited treatment options and poor outcomes, particularly for patients with relapsed or refractory (r/r) disease. Axicabtagene ciloleucel (axi-cel) and tisagenlecleuce...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Jie, Li, Junlong, Ma, Qiufei, Yang, Hongbo, Signorovitch, James, Wu, Eric
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2020
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7467403/
https://www.ncbi.nlm.nih.gov/pubmed/32524498
http://dx.doi.org/10.1007/s12325-020-01397-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7467403/
https://www.ncbi.nlm.nih.gov/pubmed/32524498
http://dx.doi.org/10.1007/s12325-020-01397-9

Ejemplares similares